Skip to main content
. 2019 May 15;9:403. doi: 10.3389/fonc.2019.00403

Figure 1.

Figure 1

MR.I T1 (a) progression under nivolumab monotherapy before start of nivolumab and ipilimumab; (b) partial remission under nivolumab and ipilimumab after 2 cycles; (c) ongoing stable disease 2 years after start of combination therapy and 7 months after end of treatment.